AbbVie Inc. ABBV
294.98 USD +1.09 (+0.37%)
At closeNov 11, 2026, 7:26 PM EST
295.13 +0.15 +0.05%
After hours · Nov 11, 7:26 PM ET
289.73 Day range 295.46
190.75 52-week range 302.93
- YTD
- +29.10%
- 1 year
- +31.00%
News
zacks.com ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell? AbbVie's strong immunology and neuroscience growth offset Humira erosion and persistent aesthetics and oncology challenges.
defenseworld.net AbbVie Inc. $ABBV Stock Bought by AlphaCore Capital LLC AlphaCore Capital LLC grew its stake in AbbVie Inc. (NYSE: ABBV) by 11.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The…
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
defenseworld.net CenterBook Partners LP Purchases New Stake in AbbVie Inc. $ABBV CenterBook Partners LP acquired a new stake in AbbVie Inc. (NYSE: ABBV) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm…
benzinga.com Reported Sunday, Allergan Aesthetics’ HALO Interim Results Show 95.7% Of 25 Adults On GLP-1 Medications Satisfied Or Very Satisfied They Still Looked Like Themselves After HA Injectables, With 39.6-Point FACE-Q Gain – HARMONY IN DIVERSITY is the first study of combined neurotoxin and filler treatment in adults on glucagon-like peptide-1 (GLP-1) medications. In this Phase 4 cohort, participants reported…
gurufocus.com Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 MedicationsPR Newswir
prnewswire.com Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications – HARMONY IN DIVERSITY is the first study of combined neurotoxin and filler treatment in adults on glucagon-like peptide-1 (GLP-1) medications. In this Phase 4 cohort, participants reported…
247wallst.com How Much Do You Need in a Roth IRA at 58 to Replace a $120,000 Salary Tax-Free? Quitting at 58 sounds simple when your savings sit in a Roth. But one hidden clock, and the wrong conversion pulled at the wrong time, can turn tax-free money into a penalty bill. Find out which…
benzinga.com Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 3.3% on an annualized basis producing an average annual return of 16.33%. Currently, AbbVie has a market capitalization of…
247wallst.com $600,000 in Dividend Stocks: How a Roth IRA Could Save You $4,460 a Year Six household-name dividend payers hand you a steady paycheck, but one of them gets taxed far harder than the other five. Find out which holding belongs in a Roth first, and how the bill snowballs…
zacks.com 2 Defensive Healthcare Stocks Hitting New 52-Week Highs: ABBV & LLY As tech stocks retreat, AbbVie (ABBV) and Eli Lilly (LLY) are hitting fresh 52-week highs, offering investors defensive healthcare exposure with compelling growth potential.
247wallst.com 5 High-Yield Dividend Stocks Paying Up to 6% With Payouts Built to Last A fat yield means nothing if the check bounces. Five payers across telecom, tobacco, pharma, real estate and pipelines show how to test coverage, and one of them carries a debt pile that could…
zacks.com Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
247wallst.com Exxon Mobil Just Raised Its Dividend for the 44th Year. Here Are 3 More Wall Street Favorites Four dividend stocks just delivered strong earnings, but free cash flow and balance sheet strength separate the ones built to keep raising payouts from the ones that just look good on paper.
benzinga.com UBS Maintains Neutral on AbbVie, Raises Price Target to $295 UBS analyst Michael Yee maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $275 to $295.
benzinga.com Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $346 Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $310 to $346.
benzinga.com AbbVie Analysts Raise Price Target After Q3 Print, Expect Growth To Reaccelerate AbbVie shares fell 2% despite Q3 revenue and EPS beats; analysts raised targets, citing immunology strength and long-term growth prospects.
benzinga.com Growth And Cyclical Sectors Lead Monday Trading Seven sectors are higher and four are lower in Monday’s regular session, with growth and cyclical sectors splitting the top of the table. The leaders are separated rather than clustered, with no…- benzinga.com Guggenheim Maintains Buy on AbbVie, Raises Price Target to $322 Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $288 to $322.
- benzinga.com Brise Pharmaceuticals Announces Its 2024 License Deal Value With AbbVie Could Reach Up To $775M For Two Of Brise's Preclinical Migraine Programs Brise Pharmaceuticals Co., Ltd. (Brise) today provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), which the companies entered in 2024. Under the terms of the collaboration…
benzinga.com Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $340 Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $300 to $340.- benzinga.com These Analysts Increase Their Forecasts On AbbVie After Strong Q3 Results AbbVie beats Q3 estimates, raises 2026 revenue and earnings outlook, while analysts lift price targets to as high as $338.
benzinga.com RBC Capital Maintains Outperform on AbbVie, Raises Price Target to $330 RBC Capital analyst Trung Huynh maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $280 to $330.
benzinga.com Canaccord Genuity Maintains Buy on AbbVie, Raises Price Target to $338 Canaccord Genuity analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $290 to $338.- benzinga.com Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $325 Cantor Fitzgerald analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $290 to $325.
- benzinga.com AbbVie, FTAI Aviation, eBay And More: CNBC’s ‘Final Trades’ CNBC traders picked eBay, GPIQ, AbbVie and FTAI, citing earnings, guidance, income potential and buybacks; shares had mixed Friday moves.
benzinga.com AbbVie Raises 2026 Outlook, Boosts Dividend AbbVie hits a new 52-week high after beating Q3 2026 earnings estimates, raising its full-year guidance, and boosting its dividend.
benzinga.com Defensives Lead Sectors In Friday Trading As Growth Trails Five sectors are higher and six are lower in Friday's regular session, with defensive sectors holding the top three positions. The leaders are clustered rather than separated, while Technology sits…
benzinga.com AbbVie Q3 2026 Earnings Call Transcript AbbVie (NYSE:ABBV) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Conference call:
AbbVie Raises FY2026 Sales Guidance from $67.600B to $67.800B vs $67.585B Est AbbVie (NYSE:ABBV) raises FY2026 sales outlook from $67.600 billion to $67.800 billion vs $67.585 billion estimate.
benzinga.com Conference call:
AbbVie Sees Q4 Adj EPS $3.83-$3.87 vs $3.89 Est; Sees Sales $18.400B vs $18.300B Est AbbVie (NYSE:ABBV) is looking for Q4 Adj EPS of $3.83-$3.87 vs $3.89 analyst estimate. sees sales of $18.400 billion vs $18.300 billion analyst estimate.- benzinga.com AbbVie Q3 Adj. EPS $3.82 Beats $3.75 Estimate, Sales $17.404B Beat $17.314B Estimate AbbVie (NYSE:ABBV) reported quarterly earnings of $3.82 per share which beat the analyst consensus estimate of $3.75 by 1.87 percent. This is a 105.38 percent increase over earnings of $1.86 per…
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Will S&P 500 open higher? Polymarket odds plunge to 14% as Wall Street reacts to Alphabet's 10% drop, rising oil, and a broad tech selloff.
benzinga.com ExxonMobil, AbbVie On Deck Friday As Energy, Drug Growth Face Test ExxonMobil headlines Friday’s reports, with investors watching whether strong energy production can sustain a sharp earnings recovery. AbbVie, Chevron, AstraZeneca, BP, Sanofi, General Dynamics,…
benzinga.com 8 Of 11 Sectors Rise Thursday As Defensives Lead Eight sectors are higher and three are lower in Thursday’s regular session, with defensive sectors holding two of the top three positions. The leaders are separated rather than clustered, with Health…
benzinga.com Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on Cancer Reed Jobs says GLP-1 drugs could help fight cancer; Yosemite fund passes $350M target.- benzinga.com AbbVie Announces Publication Of Results From Phase 3 TEMPLE Study In The Lancet Neurology; Study Results Showed Atogepant Outperformed Topiramate In Migraine Prevention Phase 3 TEMPLE study evaluated the tolerability, safety and efficacy of atogepant (QULIPTA®) compared with topiramate for the preventive treatment of migraine in adults with a history of four or more…
- benzinga.com AbbVie Submits BLA To FDA For Etentamig, Second-Gen BCMA X CD3 Bispecific Antibody T-Cell Engager Administered Intravenously For Treatment Of Adults With Relapsed Or Refractory Multiple Myeloma – Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can potentially support treatment across a broad range of…
benzinga.com Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 3.9% on an annualized basis producing an average annual return of 17.65%. Currently, AbbVie has a market capitalization of…- benzinga.com AbbVie Receives FDA Approval For Its Subcutaneous Induction Regimen For SKYRIZI To Treat Moderately To Severely Active Crohn's Disease AbbVie (NYSE:ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely…
- benzinga.com Goldman Sachs Maintains Neutral on AbbVie, Raises Price Target to $294 Goldman Sachs analyst Asad Haider maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $258 to $294.
benzinga.com What's Going On with MoonLake Immunotherapeutics Stock on Thursday? MoonLake stock rallies after AbbVie HS data misses competitor benchmarks, reinforcing sonelokimab's competitive positioning ahead of 2027 launch plans.
benzinga.com AbbVie’s Skin Disease Drug Hits Phase 3 Goal, but Efficacy Falls Short of Benchmarks: Analyst AbbVie reports Phase 3 INTREPID trial results for lutikizumab in treating moderate to severe cases of hidradenitis suppurativa.- benzinga.com AbbVie Reports Topline Results From Phase 3 INTREPID Study Evaluating Lutikizumab, Investigational Dual-Variable-Domain IL 1α/1β Antagonist, In Hidradenitis Suppurativa; Study Met Primary Endpoint And 8 Ranked Secondary Endpoints In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1Lutikizumab met 8 ranked secondary…
benzinga.com Cyclicals Top Sectors In Wednesday Trading As Defensives Trail Five sectors are higher and six are lower in Wednesday’s regular session, with cyclical sectors holding two of the top three positions alongside Technology. The leaders are separated rather than…- benzinga.com Barclays Maintains Overweight on AbbVie, Raises Price Target to $325 Barclays analyst Emily Field maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $300 to $325.
- benzinga.com Abbvie Signs ELAHERE Reimbursement LoI With The Pan-Canadian Pharmaceutical Alliance Ovarian cancer is the leading cause of death from gynecological cancers in Canada.1 In 2026, an estimated 3,000 individuals were diagnosed. Most are diagnosed at an advanced stage, and many…
- benzinga.com AbbVie Inks Multi-Year Collaboration With McLaren Racing To Be Its Official Pharmaceutical Partner Of McLaren Mastercard Formula 1 Team AbbVie (NYSE:ABBV), a global pharmaceutical leader, and McLaren Racing today announced a multi-year partnership naming AbbVie an Official Pharmaceutical Partner of the McLaren Mastercard Formula 1…
- benzinga.com AbbVie’s Dual-Target Drug Shows Phase 2 Results for Hard-to-Treat Crohn’s Disease AbbVie (NYSE:ABBV) today announced that its investigational ABBV-466, a novel dual-targeting therapy against IL-23 p19 and integrin α4β7, demonstrated higher rates of endoscopic remissiona at Week 12…
- benzinga.com Reported Saturday, AbbVie Says Rinvoq Sustains Crohn’s Endoscopic Remission Of 47.1%-64.2% At Week 144 Through About Four Years, Skyrizi Sustains Ulcerative Colitis Endoscopic Remission Of 38.8%-53.5% At Week 96 At UEGW 20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programsLatest long-term and real-world data with SKYRIZI®(risankizumab) and…